Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SK10 (Zhiyi Pharmaceutics)
- Development stage
- Preclinical
- Lead developer
- Zhiyi Pharmaceutics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SK10 is an investigational live biotherapeutic product (LBP) being developed by Zhiyi Biotechnology for the treatment of Crohn's Disease (CD). It is categorized as a biological product without prior human use, indicating that it utilizes a novel bacterial strain or microbial consortium not previously established in clinical practice. The drug is currently in the IND-enabling stage for submission to the U.S. Food and Drug Administration (FDA). As an LBP, SK10 is designed to address the underlying pathophysiology of Crohn's Disease by modulating the intestinal microbiota and host immune responses to reduce inflammation and restore gut homeostasis.
Beyond the preview
Go deeper on SK10 (Zhiyi Pharmaceutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SK10 (Zhiyi Pharmaceutics).